The fertility company Spermosens reports that the clinical study for Juno-Checked was completed in June 2025 and confirmed the test's diagnostic value, while the development of the commercial Generation 3 is progressing according to plan. This is stated in an update from the company on Tuesday.The company also expanded its patent portfolio and continues partnership discussions in Europe, the USA, Japan and Australia for a license- and partner-led market introduction.Work on the target profile for Generation 3 has resulted in planned improvements such as shorter analysis time, greater robustness and compatibility with established laboratory platforms. According to the company's timeline, Generation 3 is to be ready in the first half of 2026, followed by clinical validation in the second half of the same year.The ambition of Spermosens, communicated in March, is to achieve positive cash flow in the second half of 2026.